NEUROPTIX ANNOUNCES BREAKTHROUGH PRECLINICAL TESTS OF OPTISCAN PLATFORM FOR NON-INVASIVE EARLY DETECTION OF ALZHEIMER'S

Neuroptix Corporation, a Massachusetts-based Alzheimer's diagnostics company, announced that recent tests of its Optiscan diagnostic platform on mice demonstrated that the optical scanning system was able to detect amyloid protein aggregates in the lens of the eye prior to toxic plaque build-up in the brain.
Genetic Engineering News